香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 JD Health International Inc. 京東健康股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6618（港幣櫃台）及86618（人民幣櫃台）） 持續關連交易 終止現有合同安排 及 訂立新合同安排 茲提述招股章程有關（其中包括）原合同安排及首次公開發售豁免的「合同安排」及「關 連交易」章節，以及有關現有合同安排的公告。根據現有合同安排，宿遷天寧的登記 股東為繆欽先生（持有45%）、李婭雲女士（持有30%）及張雱女士（持有25%）。 董事會謹此宣佈，為提高行政效率，李婭雲女士於2026年3月26日訂立股權轉讓協議， 據此李婭雲女士同意將於宿遷天寧持有的30%股權轉讓予隋婷婷女士，其是京東集團 副總裁。由於一名登記股東變更，宿遷天寧、外商獨資企業及新登記股東訂立新合同 安排，現有合同安排同時終止。根據新合同安排，新登記股東為繆欽先生（持有45%）、 隋婷婷女士（持有30%）及張雱 ...

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The era of AI in healthcare is approaching, and learning from overseas development models is necessary [5] - AI products in healthcare face obstacles in data exchange, regulatory clarity, and payment systems, with the U.S. leading in data sharing and regulatory frameworks [6] - Investment opportunities in AI healthcare are centered around data resources, platforms, and clear C-end application scenarios [6] Summary by Sections Introduction - The rapid development of large model technologies, represented by Transformers, significantly impacts the healthcare industry, showing disruptive potential across various stakeholders [15] Overseas AI Healthcare Ecosystem Progress - The U.S. has established a smooth data exchange system and a regulatory framework for AI products, with a cautious approach to including AI products in insurance payment systems [6][27] - The report highlights the need for studying overseas data sharing mechanisms and regulatory policies to inform domestic AI healthcare companies [27] Investment Insights and Recommendations - Key investment lines include data asset foundations, data resource platforms, and C-end application companies with clear scenarios [6] - Notable companies to watch include: - Data asset foundations: Chuangshihui Kang, Weining Health, Wanda Information, Jiahe Meikang - Data resource platforms: Meinian Health, Jinyu Medical, Dian Diagnosis - C-end application companies: Yimaitong, Alibaba Health, JD Health [6] Regulatory and Payment Frameworks - The report discusses the evolving regulatory landscape for AI products, emphasizing the need for adaptive regulations that ensure patient safety while encouraging innovation [46] - In the U.S., over 1,400 AI products have received FDA approval, but only a few have been included in insurance reimbursement frameworks [48] - The report notes that domestic payment policies for AI products are still in exploration, with a focus on imaging products [55]

Market Updates - JD Health (06618) rose over 4.5% following a strategic partnership announcement with leading medical device brand Yuyue Medical [1] - Kangfang Biopharma (09926) increased by over 5.7% after receiving NMPA clinical trial approval for its novel tri-specific antibody drug AK150 for treating advanced malignant solid tumors [1] - Yunfeng Financial (00376) saw a significant rise of 14.18%, with a previous day increase of over 10%, amid a temporary suspension announcement related to a major stock price surge [1] - Steel stocks collectively declined, with Asia Pacific Resources (01104) down 7.59% and Maanshan Iron & Steel (00323) down 7.28% [1] Earnings Warnings and Gains - Jiuyuan Group (00827) fell over 20% after issuing a profit warning, projecting a net loss of approximately RMB 709 million for the year ending December 31, 2025, an increase from a loss of RMB 505 million in 2024 [2] - Changfeng Pharmaceutical (02652) surged nearly 43% after announcing that its inhalation powder ICF001 for treating pulmonary arterial hypertension has received NMPA acceptance for clinical trial application [2] - Yicheng Industrial (01596) rose over 76% after announcing a projected net profit of approximately RMB 334 million for the year ending December 31, 2025, compared to a net loss of RMB 57.7 million in 2024 [3] - Akeso Biopharma (09939) increased by over 10.7% following a strategic cooperation agreement with Funo Pharmaceuticals to develop a new cosmetic product [3] Other Notable Movements - Soundon Technology (02495) rose over 5% after projecting a net profit of no less than RMB 120 million for the year ending December 31, 2025, compared to a net loss of RMB 481 million in 2024 [4] - Starry Chain Group (00399) saw an increase of 18.52% after announcing a memorandum of understanding with Newbridge Acquisition Limited for potential acquisition opportunities [4] US Market Highlights - Tencent Holdings (ADR) (TCEHY.US) rose 1.11% as it welcomed Apple's adjustment of App Store commission policies in China [5] - Meta (META.US) fell 3.83%, marking its largest intraday drop since March 6, due to delays in the release of its new AI model [5] - Ulta Beauty (ULTA.US) dropped 14.24% despite strong same-store sales growth, as fourth-quarter profits fell short of expectations [5] - Bitcoin rose over 5% to $73,764, while Ethereum increased over 6.5% to $2,201.41, reflecting a positive trend in the cryptocurrency sector [6]

Market Overview - On March 11, the three major indices collectively rose, with the ChiNext Index initially increasing over 2% before retreating, while the Sci-Tech Innovation Index fell by 0.98%. Over 3,200 stocks in the market declined [1][2]. Index Performance - Shanghai Composite Index closed at 4,133.43, up by 10.30 points or 0.25% - Shenzhen Component Index closed at 14,465.41, up by 111.34 points or 0.78% - ChiNext Index closed at 3,349.53, up by 43.39 points or 1.31% - Sci-Tech Innovation Index closed at 1,774.03, down by 17.52 points or 0.98% - The total trading volume reached 2.51 trillion yuan, with 1,955 stocks rising and 3,157 stocks falling [2]. Sector Performance - The energy storage and lithium mining sectors were active throughout the day, with green energy concepts experiencing a surge. Green power stocks saw consecutive gains, and energy-saving wind power stocks hit the daily limit [2]. - The chemical sector saw a strong rally, particularly in coal and salt chemicals, with stocks like Jinniu Chemical and Zhongyan Chemical hitting the daily limit. The ongoing geopolitical conflict in the Middle East has pushed up international oil prices, supporting chemical product costs [2]. - The chemical fiber sector collectively rose, with companies like Zhongfu Shenying increasing over 14%. The price of spandex was raised, with increases of 2,000 yuan/ton for Taihe New Materials and 3,000 yuan/ton for Huahai Spandex reported [2]. Coal Sector - The coal sector experienced fluctuations, with Huadian Energy achieving consecutive gains. Other companies like China Coal Energy and Yanzhou Coal Mining also saw increases [3]. Downward Trends - The small metals sector declined, with companies like Xianglu Tungsten and Zhongtung High-tech dropping over 5%. The gas turbine sector also weakened, with stocks like Jereh and Tunan falling collectively [3]. - The "lobster" concept stocks saw a collective decline, with companies like Kunlun Wanwei and Qingyun Technology dropping over 4% [4]. Hong Kong Market - In the Hong Kong market, the Hang Seng Index fell by 0.21% and the Hang Seng Tech Index decreased by 0.14%. Most popular tech stocks declined, with Meituan, NetEase, and JD Health dropping over 2%. However, automotive stocks surged, with NIO rising over 14% and other companies like Li Auto and Xpeng increasing over 4%. NIO reported a quarterly operating profit of 1.25 billion yuan, marking the company's first quarterly profit [7].

Investment Rating - The investment rating for JD Health (06618.HK) is "Outperform the Market" [6][16] Core Insights - JD Health reported a significant revenue growth of 28% year-on-year, achieving a total revenue of 38.15 billion yuan in the second half of 2025. The growth was driven by an increase in active user numbers and a wider range of product categories, particularly in the pharmaceutical segment, which saw over 30% growth [2][9] - The company's non-IFRS net profit margin improved from 7.2% to 7.8% year-on-year, benefiting from enhanced operating profit margins, despite some offset from declines in interest income and other revenues. The management plans to increase long-term strategic investments to capitalize on structural changes in the market [3][10] Revenue Summary - For the second half of 2025, JD Health's revenue breakdown includes: - Product revenue of 31.6 billion yuan, up 27% year-on-year, with pharmaceutical revenue growth exceeding 30% and health products growing over 20% [2][9] - Service revenue increased by 34% to 6.6 billion yuan, driven by a rise in the number of advertisers [2][9] Profitability Summary - The company’s non-IFRS net profit margin increased to 7.8%, with operating profit margin improvements being a key factor. Fulfillment expenses rose from 3.1 billion yuan to 4.1 billion yuan, while sales expenses increased from 1.6 billion yuan to 2 billion yuan [3][10] - The management fee rate decreased from 2.5% to 1.4%, primarily due to reduced share-based payment expenses [3][10] Operational Data - As of the second half of 2025, JD Health had 218 million annual active users, a 19% increase year-on-year, with a main site user penetration rate of 31%. The online penetration rate in the outpatient market is currently around 15%, indicating significant growth potential [4][11] - The average transaction value saw a decline year-on-year, but this was offset by an increase in shopping frequency among users [4][11] Financial Forecast - Revenue projections for 2026 and 2027 are set at 87.18 billion yuan and 98.11 billion yuan, respectively, with a 7.9% upward adjustment from previous estimates. The adjusted net profit forecasts for the same years are 6.6 billion yuan and 7.5 billion yuan [4][16] - The company is expected to achieve a revenue of 110.4 billion yuan by 2028, with a corresponding adjusted net profit of 9 billion yuan [4][16]

证券研究报告 | 2026年03月11日 京东健康（06618.HK） 优于大市 2025H2 财报点评：收入利润增长亮眼，医药线上渗透率提升 空间大 核心观点 公司研究·海外公司财报点评 互联网·互联网Ⅱ | 证券分析师：张伦可 | 证券分析师：王颖婕 | | --- | --- | | 0755-81982651 | 0755-81983057 | | zhanglunke@guosen.com.cnwangyingjie1@guosen.com.cn | | | S0980521120004 | S0980525020001 | | 基础数据 | | | 投资评级 | 优于大市(维持) | | 合理估值 | | | 收盘价 | 49.18 港元 | | 总市值/流通市值 | 157906/157906 百万港元 | | 52 周最高价/最低价 | 71.70/27.15 港元 | | 近 3 个月日均成交额 | 475.85 百万港元 | 收入端：2025H2，公司实现营业收入 381.5 亿元，同比+28%。分拆看，1） 下半年商品收入 316 亿元，同比+27%，主要系活跃用户数增加以及产品 品类丰 ...

Group 1 - Jiangyin International maintains a "Buy" rating for BYD Company Limited with a target price of HKD 133, highlighting the launch of the second-generation blade battery and MW Flash Charge 2.0 technology, which allows for a 70% charge in 5 minutes at room temperature and 97% in 12 minutes at -20°C, alleviating user anxiety regarding charging [1] - CMB International maintains a "Buy" rating for ZTE Corporation with a target price of HKD 38.6, noting a projected 10.4% revenue growth in FY25, despite a 33.3% decline in net profit due to a higher proportion of enterprise and government business affecting gross margin [1] - CITIC Securities maintains a "Buy" rating for Bilibili Inc., indicating that the company is expected to achieve its first annual GAAP profit by Q4 2025, with advertising revenue growing by 27.4% as a core driver [1] Group 2 - Huatai Securities maintains a "Buy" rating for JD.com with a target price of HKD 147.88, reporting steady growth in retail with double-digit growth in daily categories for five consecutive quarters and a 40% increase in user purchase frequency [2] - CITIC Jiantou maintains a "Buy" rating for JD Health with a target price of HKD 69.22, forecasting a 26.3% revenue increase and a 36.3% rise in Non-IFRS net profit in 2025, driven by prescription drugs and platform advertising revenue [2] Group 3 - Huatai Securities maintains a "Buy" rating for JD Logistics with a target price of HKD 17.1, projecting an 18.8% revenue increase in 2025, with a significant rise in integrated supply chain revenue [3] - Tianfeng Securities maintains a "Buy" rating for Bosideng, reporting an 8.3% revenue increase in brand down jackets for FY26H1, supported by designer collaborations and store reform strategies [4] Group 4 - Tianfeng Securities maintains a "Buy" rating for Nine Dragons Paper Holdings, noting a 318.8% increase in net profit for FY26H1, benefiting from integrated pulp and paper operations and new production lines [5] - Zhongtai International maintains a "Buy" rating for Weisheng Holdings with a target price of HKD 32.68, expecting a 42% to 50% increase in net profit for FY25, driven by smart distribution business growth [7] Group 5 - Shenwan Hongyuan maintains a "Buy" rating for Xidi Intelligent Driving, reporting a 57.9% revenue increase with 304 autonomous mining trucks delivered in H1 2025, and a significant order backlog [8]

京东健康（6618.HK）2025 年度业绩公告点评 高质量增长延续，AI+供应链全面赋能健康服务 glmszqdatemark [盈利预测与财务指标 Table_Forcast] | 单位/百万人民币 | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | | 营业收入 | 73,441 | 85,574 | 97,991 | 108,053 | | 增长率（%） | 26.3 | 16.5 | 14.5 | 10.3 | | 经调整净利润 | 6,533 | 6,582 | 7,605 | 8,364 | | 增长率（%） | 36 | 1 | 16 | 10 | | EPS(基于经调整净利润） | 2.03 | 2.05 | 2.37 | 2.61 | | P/E(基于经调整净利润） | 21 | 21 | 18 | 17 | | P/B | 2.3 | 2.0 | 1.8 | 1.6 | 资料来源：Wind，国联民生证券研究所预测（注：股价为 2026 年 03 月 09 日收盘价,汇率 1HKD=0.88RMB） 推荐 维持 ...

研究报告 Research Report 2025 年收入和利润超市场预期，线下药店及 AI 布局稳步推进 FY2025 top-line and bottom-line results surpassed market consensus, as offline pharmacy network expansion and AI strategy advanced on track [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$49.18 目标价 HK$71.07 HTI ESG 4.0-4.0-4.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$157.91bn / US$20.19bn 日交易额 (3 个月均值) US$60.69mn 发行股票数目 3,211mn 自由流通股 (%) 32% 1 年股价最高最低值 HK$69.65-HK$27.80 注：现价 ...

Group 1 - The report highlights the strong performance of the wind power hydraulic lubrication leader, Chuanrun Co., which is advancing into AIDC liquid cooling, benefiting from the rising industry demand [4] - The company has a solid global layout in high-end energy equipment manufacturing, focusing on offshore wind power and liquid cooling, with overseas revenue reaching 43.64 million yuan in the first half of 2025, a year-on-year increase of 375.7% [4] - The liquid cooling technology is expected to gain traction due to stricter energy consumption regulations for data centers, with NVIDIA's next-generation Rubin chip adopting a fully liquid cooling solution, enhancing market potential [5][6] Group 2 - The asset allocation report emphasizes the continuity of the policy framework for 2026, with a focus on expanding domestic demand and managing financial risks in real estate and local debts [8][9] - The macroeconomic environment is supported by a strong fiscal policy and moderate monetary easing, which is expected to stabilize the equity market [9] - The report outlines a shift towards more execution-oriented industrial policies, enhancing visibility for commercial applications and orders in various sectors [9] Group 3 - The AI demand is projected to exceed expectations, with Shengquan Group positioned to benefit from the high-performance resin market, which is expected to see rapid growth [11] - The company is the largest domestic supplier of electronic chemical materials, with a comprehensive product matrix for high-frequency and high-speed copper-clad laminates [12] - Shengquan Group is expanding its production capacity with new projects set to come online in 2026, including 2000 tons/year of PPO/OPE resin and 1500 tons/year of hydrocarbon resin [12] Group 4 - The automotive industry report discusses the competitive landscape of Robotaxi in the US and China, highlighting Waymo and Tesla as key players in the US market [16][17] - In China, companies like Pony.ai and WeRide are leading the Robotaxi sector, with significant advancements in operational areas and regulatory support for autonomous driving [18] - The report suggests investment opportunities in leading Robotaxi companies and related technologies, emphasizing the acceleration of commercialization in both markets [19] Group 5 - The macroeconomic commentary on the government work report for 2026 outlines a growth target of 4.5%-5%, with a focus on expanding domestic demand and optimizing supply [20][22] - The report emphasizes the importance of employment, with a target of over 12 million new urban jobs, aligning with the economic growth objectives [23] - The fiscal policy remains proactive, with a projected budget expenditure of 30 trillion yuan for 2026, reflecting a commitment to sustainable growth [25][26] Group 6 - The report indicates a strong emphasis on technology innovation as a driver for new economic momentum, with significant increases in R&D investment expected [36][37] - The focus on high-level self-reliance in technology is set to support the development of new industries and enhance the digital economy's contribution to GDP [37][38] - The report outlines plans for substantial investments in modernizing the industrial system, with a focus on high-quality development and technological advancements [38]